Hypera S.A - Asset Resilience Ratio
Hypera S.A (HYPE3) has an Asset Resilience Ratio of 5.72% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2025)
This chart shows how Hypera S.A's Asset Resilience Ratio has changed over time. Check Hypera S.A strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Hypera S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see HYPE3 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$1.64 Billion | 5.72% |
| Short-term Investments | R$0.00 | 0% |
| Total Liquid Assets | R$1.64 Billion | 5.72% |
Asset Resilience Insights
- Limited Liquidity: Hypera S.A maintains only 5.72% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Hypera S.A Industry Peers by Asset Resilience Ratio
Compare Hypera S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329 |
Drug Manufacturers - Specialty & Generic | 5.92% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for Hypera S.A (2009–2025)
The table below shows the annual Asset Resilience Ratio data for Hypera S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.72% | R$1.64 Billion ≈ $320.90 Million |
R$28.59 Billion ≈ $5.61 Billion |
-1.12pp |
| 2024-12-31 | 6.84% | R$1.68 Billion ≈ $329.79 Million |
R$24.56 Billion ≈ $4.82 Billion |
-3.56pp |
| 2023-12-31 | 10.41% | R$2.55 Billion ≈ $500.42 Million |
R$24.51 Billion ≈ $4.81 Billion |
-0.83pp |
| 2022-12-31 | 11.23% | R$2.67 Billion ≈ $523.67 Million |
R$23.76 Billion ≈ $4.66 Billion |
+2.57pp |
| 2021-12-31 | 8.66% | R$1.72 Billion ≈ $336.94 Million |
R$19.82 Billion ≈ $3.89 Billion |
-13.83pp |
| 2020-12-31 | 22.49% | R$3.88 Billion ≈ $761.38 Million |
R$17.25 Billion ≈ $3.38 Billion |
+10.58pp |
| 2019-12-31 | 11.92% | R$1.42 Billion ≈ $278.77 Million |
R$11.92 Billion ≈ $2.34 Billion |
-1.53pp |
| 2018-12-31 | 13.45% | R$1.42 Billion ≈ $278.53 Million |
R$10.56 Billion ≈ $2.07 Billion |
+1.52pp |
| 2017-12-31 | 11.93% | R$1.21 Billion ≈ $237.13 Million |
R$10.13 Billion ≈ $1.99 Billion |
+2.71pp |
| 2016-12-31 | 9.22% | R$1.05 Billion ≈ $205.90 Million |
R$11.38 Billion ≈ $2.23 Billion |
+11.90pp |
| 2015-12-31 | -2.68% | R$-423.77 Million ≈ $-83.15 Million |
R$15.82 Billion ≈ $3.10 Billion |
-0.50pp |
| 2014-12-31 | -2.17% | R$-301.92 Million ≈ $-59.24 Million |
R$13.89 Billion ≈ $2.73 Billion |
-1.52pp |
| 2013-12-31 | -0.65% | R$-81.63 Million ≈ $-16.02 Million |
R$12.50 Billion ≈ $2.45 Billion |
-0.04pp |
| 2012-12-31 | -0.62% | R$-78.00 Million ≈ $-15.31 Million |
R$12.66 Billion ≈ $2.48 Billion |
-0.63pp |
| 2011-12-31 | 0.01% | R$1.71 Million ≈ $335.93K |
R$13.33 Billion ≈ $2.61 Billion |
+0.35pp |
| 2010-12-31 | -0.34% | R$-33.87 Million ≈ $-6.65 Million |
R$9.99 Billion ≈ $1.96 Billion |
-0.22pp |
| 2009-12-31 | -0.12% | R$-7.28 Million ≈ $-1.43 Million |
R$6.09 Billion ≈ $1.20 Billion |
-- |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Co… Read more